146 related articles for article (PubMed ID: 38545829)
21. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
22. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
23. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer mortality in areas with high and low prostate cancer incidence.
Stattin P; Carlsson S; Holmström B; Vickers A; Hugosson J; Lilja H; Jonsson H
J Natl Cancer Inst; 2014 Mar; 106(3):dju007. PubMed ID: 24610909
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer incidence, mortality and survival trends in Estonia, 1995-2014.
Innos K; Baburin A; Kotsar A; Eiche IE; Lang K
Scand J Urol; 2017 Dec; 51(6):442-449. PubMed ID: 29092653
[TBL] [Abstract][Full Text] [Related]
26. Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements.
Zitricky F; Försti A; Hemminki A; Hemminki O; Hemminki K
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627160
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer in Denmark 1978-2009--trends in incidence and mortality.
Outzen M; Brasso K; Martinussen N; Christensen J; Tjønneland A; Friis S; Olsen A
Acta Oncol; 2013 May; 52(4):831-6. PubMed ID: 22809166
[TBL] [Abstract][Full Text] [Related]
28. Trends in survival of prostate cancer in southeastern Netherlands, 1971-1989.
Post PN; Kil PJ; Coebergh JW
Int J Cancer; 1999 May; 81(4):551-4. PubMed ID: 10225443
[TBL] [Abstract][Full Text] [Related]
29. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
[TBL] [Abstract][Full Text] [Related]
30. Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA.
Seikkula HA; Kaipia AJ; Rantanen ME; Pitkäniemi JM; Malila NK; Boström PJ
Acta Oncol; 2017 Jul; 56(7):971-977. PubMed ID: 28406044
[TBL] [Abstract][Full Text] [Related]
31. The 1989 patterns of care study for prostate cancer: five-year outcomes.
Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
[TBL] [Abstract][Full Text] [Related]
32. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
33. Conditional survival for long-term colorectal cancer survivors in the Netherlands: who do best?
van Erning FN; van Steenbergen LN; Lemmens VEPP; Rutten HJT; Martijn H; van Spronsen DJ; Janssen-Heijnen MLG
Eur J Cancer; 2014 Jul; 50(10):1731-1739. PubMed ID: 24814358
[TBL] [Abstract][Full Text] [Related]
34. Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease.
Hsiao W; Moses KA; Goodman M; Jani AB; Rossi PJ; Master VA
J Urol; 2010 Aug; 184(2):512-8. PubMed ID: 20620410
[TBL] [Abstract][Full Text] [Related]
35. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
36. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden.
Johansson JE; Holmberg L; Johansson S; Bergström R; Adami HO
JAMA; 1997 Feb; 277(6):467-71. PubMed ID: 9020270
[TBL] [Abstract][Full Text] [Related]
37. Conditional survival of cancer patients: an Australian perspective.
Yu XQ; Baade PD; O'Connell DL
BMC Cancer; 2012 Oct; 12():460. PubMed ID: 23043308
[TBL] [Abstract][Full Text] [Related]
38. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden.
Aly M; Leval A; Schain F; Liwing J; Lawson J; Vágó E; Nordström T; Andersson TM; Sjöland E; Wang C; Eloranta S; Akre O
Scand J Urol; 2020 Apr; 54(2):115-121. PubMed ID: 32266854
[No Abstract] [Full Text] [Related]
39. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
Aus G; Robinson D; Rosell J; Sandblom G; Varenhorst E;
Cancer; 2005 Mar; 103(5):943-51. PubMed ID: 15651057
[TBL] [Abstract][Full Text] [Related]
40. Conditional survival for longer-term survivors from 2000-2004 using population-based cancer registry data in Osaka, Japan.
Ito Y; Nakayama T; Miyashiro I; Ioka A; Tsukuma H
BMC Cancer; 2013 Jun; 13():304. PubMed ID: 23800306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
